Specificity of lysis of MCL samples.

(A) PBMCs from a patient with MCL containing 50% CD20⁺cells were lysed with rituximab and 25% human complement in the absence (black bars) or presence (hatched bars) of anti-CD55 and or anti-CD59 antibodies (10 μg/mL). The percentage of CD20⁺cells was determined and is indicated by the broken line. (B) The MCL B cells were purified by negative selection, reaching 98% CD20⁺, and lysis was repeated as in (A).